Each step. Every patient. Exactly what you need.

Personalize Colorectal Cancer Treatment with Myriad Oncology Tests

Revealing the full picture with germline and tumor genomic testing for colorectal cancer

Uncover hidden risks

1 in 5 patients have a family history of the disease, indicating familial clustering1

Don’t miss crucial information

Tumor testing alone can overlook up to 10% of key genetic variants2

Bridge the testing gap

Currently, only 6% of patients receive potentially life-saving genetic insights1,4

How would you approach Fiona’s germline and tumor genomic testing?

Based on national guideline for cancer care,1,2,3 Fiona meets the criteria for combined germline and tumor genomic testing. These guidelines, established by leading oncology organizations, recommend comprehensive genetic profiling for patients like Fiona to inform treatment decisions and assess hereditary risk factors.

What did Fiona’s testing from Myriad Oncology reveal?

  • GERMLINE TESTING

    Revealing hereditary risks

    The MyRisk® Hereditary Cancer Test identified a positive MLH1 pathogenic variant in Fiona's case, diagnosing Lynch syndrome. This critical information enables:

    • Lifelong enhanced cancer surveillance for Fiona
    • Preventive measures to help reduce cancer risks
    • Essential genetic testing for family members
    DOWNLOAD THE CASE STUDY
  • TUMOR GENOMIC PROFILING

    Guiding Treatment and Clinical Trial Opportunities

    Precise Tumor® Molecular Profile Test uncovered:

    • FDA-approved therapy targets: MLH1 and KRAS variants
    • High Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI)
    • PD-L1 IHC status: Negative
    • 31 relevant clinical trials for Fiona's specific cancer profile
    DOWNLOAD THE CASE STUDY
  • CLINICAL IMPACT

    Tailoring Treatment Strategies

    • Lynch syndrome diagnosis necessitates lifelong enhanced cancer surveillance
    • Prompts germline genetic testing for her family
    • Informs immunotherapy and targeted treatment options
    DOWNLOAD THE CASE STUDY

Revealing hereditary risks

The MyRisk® Hereditary Cancer Test identified a positive MLH1 pathogenic variant in Fiona's case, diagnosing Lynch syndrome. This critical information enables:

  • Lifelong enhanced cancer surveillance for Fiona
  • Preventive measures to help reduce cancer risks
  • Essential genetic testing for family members
DOWNLOAD THE CASE STUDY

Guiding Treatment and Clinical Trial Opportunities

Precise Tumor® Molecular Profile Test uncovered:

  • FDA-approved therapy targets: MLH1 and KRAS variants
  • High Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI)
  • PD-L1 IHC status: Negative
  • 31 relevant clinical trials for Fiona's specific cancer profile
DOWNLOAD THE CASE STUDY

Tailoring Treatment Strategies

  • Lynch syndrome diagnosis necessitates lifelong enhanced cancer surveillance
  • Prompts germline genetic testing for her family
  • Informs immunotherapy and targeted treatment options
DOWNLOAD THE CASE STUDY

See what Myriad Oncology’s test revealed for another patient

DOWNLOAD THE CASE STUDY

Infographic of the simplified approach to Myriad Oncology’s patient pathway showing the different Myriad Oncology tests available for high-risk unaffected, diagnosed, progression, and survivorship patient types.Infographic of the simplified approach to Myriad Oncology’s patient pathway showing the different Myriad Oncology tests available for high-risk unaffected, diagnosed, progression, and survivorship patient types.

MyRisk STAT:

Right surgery. Right answer. Right now.

There should not be a trade-off between turnaround time and receiving an accurate, comprehensive risk assessment when determining surgical treatment for eligible surgery-pending colorectal cancer patients.

The MyRisk STAT Test, an expedited version of the MyRisk Hereditary Cancer Test, was developed for results without the wait.

Learn more about MyRisk STAT
7 days

MyRisk STAT Test results available <7 days from sample receipt for eligible Breast, Pancreatic, and colorectal cancer patients†

Ongoing support for your practice to optimize the patient care you provide

Myriad Oncology provides a comprehensive suite of services and workflow solutions that simplify germline and tumor genomic testing, all at no additional cost to the clinic or patient.

Patient education

Pre- and post-test education as live, point-of-care sessions with a board-certified Genetic Counselor

Affordability

Transparent pricing with personalized cost estimates, financial assistance, and other affordability options, including direct pay

Faster results

Consolidated germline and tumor genomic results are available on average of 14 days (as fast as 7 days for surgery-pending patients) after lab receives the sample

The MyRisk Management Tool

Streamline germline and tumor genomic results into an easy-to-follow report

Provider support

Medical Science Liason’s support providers and their teams in answering clinical, testing, and results-related questions

Lifetime commitment

Myriad’s Variant Classification Program includes a Lifetime Reclassification Commitment to send amended reports if a variant of uncertain significance (VUS) is reclassified and is clinically actionable

MYRIAD ONCOLOGY

Each step. Every patient. Exactly what you need.

EXPLORE THE FULL MYRIAD ONCOLOGY PORTFOLIO

Get started with Myriad Oncology. Request more information from our team.

Get started with Myriad Oncology

Request more information about how Myriad’s Oncology solutions can benefit you/your patients.


Don't know your NPI? Click Here

By submitting your personal information, you agree to be contacted with newsletters, marketing or promotional materials, and other information that may be of interest to you. You may opt-out of receiving communications from us by following the unsubscribe link or the instructions provided in the communication we send. For further information on our privacy practices and commitment to protecting your privacy, please visit our Privacy Notice.

Hidden Fields











Hidden test fields

Contact Information

†Patients with government payers (Medicare, Medicare Advantage, TriCare) are not eligible for MyRisk STAT.

  1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Colon cancer 4.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed August 26, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  2. Tung N, Ricker C, Messersmith H, et al. Selection of Germline Genetic Testing Panels in Patients With Cancer: ASCO Guideline. J Clin Oncol. 2024;42(21):2599-2615.
  3. Chakravarty D, Johnson A, Sklar J, et al. Somatic Genomic Testing in Patients with Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. J Clin Oncol. 2022;40(11):1231-1258.
  4. Kurian AW, Abrahamse P, Furgal A, et al. Germline genetic testing after cancer diagnosis. JAMA. 2023;330(1):43-51.
  5. Schrock-Kelley S, Souter V, Hall MJ, et al. Poor compliance with germline testing recommendations in colorectal cancer patients undergoing molecular residual disease testing. Commun Med. 2024;4:18.

©2025 Myriad Genetics, Inc. Myriad Genetics, Myriad Oncology, MyRisk, Precise Tumor, and their respective logos, are either trademarks or registered trademarks of Myriad Genetics, Inc. and its subsidiaries in the United States and other jurisdictions.

Locations

United States
Europe
Japan